Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 8/28/2024 | $180.00 | Overweight | Wells Fargo |
| 6/26/2024 | $180.00 → $155.00 | Hold → Buy | Deutsche Bank |
| 6/18/2024 | Neutral | Guggenheim | |
| 12/4/2023 | Buy → Hold | The Benchmark Company | |
| 7/20/2023 | $185.00 | Overweight | Wells Fargo |
| 7/5/2023 | $220.00 | Overweight | JP Morgan |
| 3/28/2023 | $230.00 | Buy | The Benchmark Company |
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise s
Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today's webcast a
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held November 18-19 in New York City. Olivier Loeillot, Chief Executive Officer, and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Tuesday, November 19,
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required
Wolfe Research initiated coverage of Repligen with a rating of Peer Perform
Wells Fargo initiated coverage of Repligen with a rating of Overweight and set a new price target of $180.00
Deutsche Bank upgraded Repligen from Hold to Buy and set a new price target of $155.00 from $180.00 previously
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
10-Q - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today's webcast a
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required
Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue guidance within previous range for fiscal year 2024; adjusted EPS guidance unchanged WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and acce
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Justin Bowers upgraded the rating for Repligen Corporation (NASDAQ:RGEN) from Hold to Buy, but lowered the price target from $180 to $155. Repligen shares fell 0.4% to close at $123.15 on Tuesday. See how other analysts view this stock. Wolfe Research analyst Steven Chubak upgraded Robinhood Markets, Inc. (NASDAQ:HOOD) from Peer Perform to Outperform, while announcing a price target of $29. Robinhood shares gained 3.6% to close at $22.14 on Tuesday. See how other